Beam Therapeutics (BEAM)
(Delayed Data from NSDQ)
$18.83 USD
-0.88 (-4.46%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $18.82 -0.01 (-0.05%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BEAM 18.83 -0.88(-4.46%)
Will BEAM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BEAM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BEAM
Vir Biotechnology, Inc. (VIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
BEAM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will Beam Therapeutics Inc. (BEAM) Report Negative Q2 Earnings? What You Should Know
Innovation ETF (ARKK) Hits New 52-Week High
3 Promising Genomics Stocks to Keep an Eye On in 2025
Other News for BEAM
Cathie Wood Starts This Volatile Week with $13M Buy and a Key Sell-Off
Cathie Wood's ARK Investment buys 659K shares of Beam Therapeutics today
Cathie Wood's ARK Investment buys 29K shares of Beam Therapeutics today
Cathie Wood's ARK Investment buys 55K shares of Beam Therapeutics today
Cathie Wood's Ark Invest Continues To Offload Coinbase, Bets Big On SoFi Technologies